J&J will help get regulatory approval for InsuPad, which reduces injected insulin uptake speed in diabetics by nearly 50%,
The share of Israeli company InsuLine Medical Ltd. (TASE: INSL) is attracting a great deal of attention today, after the company reported it had signed a memorandum of understanding with US healthcare giant Johnson and Johnson.
Under the memorandum of understanding, InsuLine and Johnson and Johnson will cooperate immediately in obtaining regulatory approval for marketing InsuPad, which reduces injected insulin uptake speed in diabetics by near 50%. Johnson and Johnson will also manage registration procedures with the various authorities.
Help employers find you! Check out all the jobs and post your resume.
